AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00357955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role modeling
Description: learning from peers with similar disease and problems
Study NCT03624556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG FontUp
Description: Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
Study NCT03624556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FontUp
Description: Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
Study NCT04497155 — intervention group
Intervention type: DRUG
Intervention: Norepinephrine
Description: Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
Study NCT02757768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
Study NCT02757768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Study NCT02757768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Study NCT02757768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin Hydrochloride
Description: Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Study NCT00357955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacologic case management
Description: provided by clinical pharmacists following pre-established algorithms
Study NCT04480307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temelimab 18 mg/kg
Description: temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Study NCT04480307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temelimab 36 mg/kg
Description: temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Study NCT04480307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temelimab 54 mg/kg
Description: temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Study NCT04480307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Study NCT04541706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
Study NCT01996046 — intervention group
Intervention type: OTHER
Intervention: FDG PET/CT scan
Description: \[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
Study NCT06675474 — intervention group
Intervention type: OTHER
Intervention: Clinical periodontal measurements
Description: Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.
Study NCT06675474 — intervention group
Intervention type: OTHER
Intervention: Saliva sampling
Description: The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.
Study NCT06675474 — intervention group
Intervention type: OTHER
Intervention: Serum Sampling
Description: 5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.
Study NCT06675474 — intervention group
Intervention type: OTHER
Intervention: GCF sampling
Description: GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.
Study NCT06675474 — intervention group
Intervention type: OTHER
Intervention: Subgingival plaque sampling
Description: Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
Study NCT01057771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
Study NCT01057771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
Study NCT04060017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin Calcium
Description: Liquid leucovorin calcium dosed by weight
Study NCT04060017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02323620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BM-MC
Description: Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
Study NCT06691789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social support
Description: This intervention includes a social support given to the students during COVID-19 pandemic
Study NCT02562014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 75g glucose
Study NCT02562014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inulin
Description: 75g glucose plus 24g inulin
Study NCT02562014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistant Starch
Description: 75g glucose plus 28.2g resistant starch
Study NCT04108910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Guidance UTI
Study NCT02561455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral tablet
Study NCT03677024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN arm
Description: Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
Study NCT03681340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study NCT03681340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study NCT03681340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study NCT03681340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study NCT05545462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
Study NCT05545462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMMON SALT
Description: THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
Study NCT03534934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight
Study NCT03534934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine Pregnancy Test
Description: Urine pregnancy test done on woman of childbearing potential.
Study NCT03534934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
Study NCT03534934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
Study NCT03534934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Duel-energy X-ray absorptiometry scan
Description: Bone density measurement
Study NCT03534934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi-detector computed tomography
Description: Hip and ankle CT scan
Study NCT03534934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry scan
Description: Vertebral fracture assessment
Study NCT01041495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclobenzaprine ER (AMRIX)
Description: active drug
Study NCT01041495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for cyclobenzaprine ER (AMRIX)
Study NCT01353235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
Study NCT06690450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer® 200 mg
Description: A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
Study NCT06690450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer® 100 mg
Description: A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
Study NCT06690125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Classical and computerized assessment
Description: Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)
Study NCT02946411 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Glucose level will be measured after cardiac surgery.
Study NCT04279093 — intervention group
Intervention type: OTHER
Intervention: No intervention, but participants will use a smartphone app daily to complete the EPDS
Description: No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
Study NCT06144658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset / Hololens 2 or Varjo XR3
Description: Augmented Reality Headset
Study NCT04669197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel protein bound
Description: combination therapy
Study NCT01077505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide 50mg weekly subcutaneous injection
Study NCT01077505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (Brevicon)
Description: Oral contraceptive (Brevicon)
Study NCT01353235 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: no drug administered
Study NCT03206294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacist assessment
Description: St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
Study NCT04669197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: combination therapy
Study NCT04669197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: combination therapy
Study NCT04669197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: combination therapy
Study NCT02902978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130
Study NCT02902978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6130 matched placebo
Study NCT02811601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEAL surgery
Description: Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
Study NCT04253964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
Study NCT04253964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
Study NCT04253964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
Study NCT04253964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
Study NCT04253964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)
Description: The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Study NCT04253964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLQ-C30 Global Health/Quality of Life Questionnaire
Description: 30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
Study NCT01421771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive Agents
Description: Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator
Study NCT01421771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihypertensive Agents
Description: Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator
Study NCT01421771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry weight Challenge
Description: Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
Study NCT01421771 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry weight Challenge
Description: Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
Study NCT01421771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extend dialysis treatment time and re-challenge estimated dry weight
Description: Extend dialysis treatment time and re-challenge estimated dry weight
Study NCT01421771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Extend dialysis treatment time and re-challenge estimated dry weight
Description: Extend dialysis treatment time and re-challenge estimated dry weight
Study NCT01218828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LVEDP -Based hydration strategy
Study NCT01218828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hydration
Study NCT02863159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis Multifocal 1-Piece IOL
Description: +2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
Study NCT06191536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Study NCT06191536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Study NCT04253964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes
Description: Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
Study NCT04253964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
Study NCT00898378 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Description: gene expression analysis
Study NCT00898378 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: polymerase chain reaction
Study NCT06191536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises
Study NCT01496196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 500 mg/5 ml 3-4 times a day
Study NCT01496196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid
Description: 500 mg/5 ml 3-4 times a day
Study NCT02039700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg
Study NCT02039700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]lesinurad (100 μg per 10 mL)
Study NCT04870164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensovibep
Description: The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.
Study NCT00898378 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Description: polymorphism analysis
Study NCT00898378 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis
Study NCT00898378 — intervention group
Intervention type: GENETIC
Intervention: proteomic profiling
Description: proteomic profiling
Study NCT00898378 — intervention group
Intervention type: OTHER
Intervention: gas chromatography
Description: gas chromatography
Study NCT01680601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Description: RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
Study NCT01680601 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03605992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Rehab
Description: This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).